yahoo_financeOriginal article
Invivyd’s Covid-directed mAb hits Phase III safety goals
Phase 3positivePositive
AI Analysis
Summary
Invivyd's COVID-directed monoclonal antibody has met safety goals in Phase III clinical testing. The positive safety data represents progress in the company's development of this therapeutic candidate.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Hit Phase III safety goals
Importance:6/10
Sentiment:
0.70
COVID-19monoclonal antibodyPhase 3safety
Related Companies
Read the original article
Published by yahoo_finance on September 30, 2026 4:19 PM